Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, NEUROCRINE BIOSCIENCES, INC. reported revenue of $2.86B, up 21.4% year over year. Operating margin was 21.6% and net margin 16.7%, on a free-cash-flow margin of 26.2% with capital expenditure at 1.2% of revenue. Every figure is computed directly from NBIX's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $2.86B | 21.6% | 16.7% |
| FY2024 | $2.36B | 24.2% | 14.5% |
| FY2023 | $1.89B | 13.3% | 13.2% |
| FY2022 | $1.49B | 16.7% | 10.4% |
| FY2021 | $1.13B | 9.0% | 7.9% |
How does NBIX compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.